Department of Urology, Chhatrapati Shahuji Maharaj Medical University, Lucknow, India.
J Endourol. 2009 Dec;23(12):2007-11. doi: 10.1089/end.2009.0009.
A prospective randomized study was undertaken wherein transurethral resection of bladder tumor (TURBT) was performed along with transurethral resection of the prostate (TURP) in the same sitting (group A) in patients with bladder tumor and urodynamically proven bladder outflow obstruction. The outcome (recurrence and progression of superficial transitional cell carcinoma) was compared with patients who underwent TURBT and TURP in two separate sittings (group B) approximately 6 months apart.
Between January 2002 and December 2007, 48 patients were randomized for this study. The inclusion and exclusion criteria are described below. The patients were followed up according to standard protocols. The two groups were compared for the recurrence and progression of the bladder tumor.
Mean age in both the groups were similar (group A = 56.06 +/- 4.45 years, group B = 57.36 +/- 3.65 years). The mean duration of follow-up was also similar between the two groups (group A, 35.71 +/- 12.8 months; group B, 37.55 +/- 14.12 months; P > 0.05). In group A, 12 (50%) patients had recurrence, while in group B, 11 (42.85%) patients had recurrence. The differences in recurrence, mean elapsed time to recurrence, and progression of tumor between the two groups were statistically insignificant.
TURBT and TURP can be performed simultaneously without any increased risk of recurrence and progression of tumor, if performed in a properly selected group of patients.
本前瞻性随机研究中,对伴有尿动力学证实膀胱出口梗阻的膀胱肿瘤患者,同期行经尿道膀胱肿瘤电切术(TURBT)联合经尿道前列腺电切术(TURP)(A 组),并与分期行 TURBT 和 TURP(间隔约 6 个月,B 组)的患者进行比较,评估结局(表浅性移行细胞癌的复发和进展)。
2002 年 1 月至 2007 年 12 月,48 例患者被随机分为两组。纳入和排除标准如下。所有患者均按照标准方案进行随访。比较两组患者的膀胱肿瘤复发和进展情况。
两组患者的平均年龄相似(A 组=56.06 ± 4.45 岁,B 组=57.36 ± 3.65 岁)。两组的平均随访时间也相似(A 组 35.71 ± 12.8 个月,B 组 37.55 ± 14.12 个月;P>0.05)。A 组 12 例(50%)患者复发,B 组 11 例(42.85%)患者复发。两组患者的复发率、复发中位时间及肿瘤进展率差异无统计学意义。
如果选择合适的患者群体,同期行 TURBT 和 TURP 并不会增加肿瘤复发和进展的风险。